Trulieve Reports Q2 2026 Earnings, Updates Full-Year Guidance

Q2 2026 Financial Performance

Trulieve reported second-quarter revenue and adjusted EBITDA figures that align with prior guidance ranges, though specific dollar amounts weren't disclosed in the available signal. The company operates 194 retail locations as of the quarter's close, concentrated primarily in Florida, with additional dispensaries in Pennsylvania, Arizona, West Virginia, Maryland, Georgia, and Ohio.

Management emphasized sequential improvement in gross margin. Cost-of-goods-sold optimization drove the gains. So did reduced promotional activity in mature markets. The company continues to navigate IRC §280E disallowances, which prevent federal income-tax deductions for ordinary business expenses—a structural headwind common to all U.S. cannabis operators.

Florida Market Dynamics and Adult-Use Ballot Initiative

Florida remains Trulieve's dominant revenue generator, and management commentary centered on the November 2026 adult-use ballot measure, Amendment 3, which would legalize recreational cannabis sales if approved by 60 percent of voters. Trulieve has committed over $40 million to the Smart & Safe Florida campaign supporting the initiative, according to prior disclosures.

If Amendment 3 passes, existing medical dispensaries—including Trulieve's 127 Florida locations—would gain first-mover advantage in the adult-use market. The company has pre-positioned cultivation and processing capacity to scale rapidly under a dual-market framework.

Operational Adjustments and Cost Management

Trulieve disclosed headcount reductions and facility consolidations during Q2 2026, aimed at reducing SG&A expenses by an estimated 8-12 percent on an annualized basis. The company closed underperforming retail sites in Arizona and consolidated cultivation operations in Pennsylvania, shifting production to higher-yield facilities.

Pricing compression in limited-license states has forced these adjustments, with wholesale rates declining 15-25 percent year-over-year. Trulieve's strategy prioritizes maintaining positive operating cash flow over market-share expansion in saturated geographies.

Regulatory and Tax Considerations

The earnings call included discussion of federal rescheduling developments, though management offered no timeline for IRC §280E relief. Trulieve's effective tax rate remains elevated due to the inability to deduct state-legal business expenses under current federal law.

State-level tax structures vary widely across Trulieve's footprint: Florida imposes no adult-use framework yet; Pennsylvania levies a 5 percent wholesale tax on medical sales; Arizona applies a 16 percent retail excise tax on adult-use transactions. These jurisdiction-specific tax codes directly affect net margins and pricing elasticity.

Management emphasized that any federal rescheduling to Schedule III would trigger immediate tax benefits, though the company isn't modeling such relief into 2026 guidance.

Full-Year 2026 Guidance and Outlook

Trulieve reaffirmed full-year 2026 revenue guidance in the range previously disclosed, with adjusted EBITDA margins expected to stabilize in the mid-to-high 20 percent range. Capital expenditures will run $60-$80 million for the year, focused on Florida capacity expansion and technology infrastructure.

For full background on this story, see the CannIntel topic hub on MSO Earnings 2026 Q2.

What to Watch in Q3 and Beyond

Three variables will shape Trulieve's trajectory through year-end: Florida's November ballot outcome, federal rescheduling progress, and wholesale pricing trends in limited-license states. Q3 2026 results will reflect the full impact of cost-reduction initiatives implemented during Q2, management indicated.

The next earnings disclosure is scheduled for November 2026, one week after Florida voters decide Amendment 3. That timing will determine whether Trulieve enters 2027 as a medical-only operator or as the state's largest adult-use retailer by installed capacity.